Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 5/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16676870 | 0.93 | POLB (0.78) | POLBALDH1A1HTTMEN1KMT2A | |
| SCHEMBL19291025 | 0.91 | POLB (0.78) | POLBALDH1A1HTTMEN1KMT2A | |
| SCHEMBL16667802 | 0.88 | POLB (1.00) | POLBALDH1A1HTTTP53MAPT | |
| SCHEMBL16667845 | 0.80 | POLB (0.85) | POLBALDH1A1HTTTP53MAPT | |
| SCHEMBL16668174 | 0.80 | POLB (0.81) | POLBALDH1A1HTTMEN1KMT2A | |
| SCHEMBL16668018 | 0.79 | POLB (0.84) | POLBALDH1A1HTTTP53MAPT | |
| SCHEMBL16667735 | 0.76 | POLB (0.78) | POLBALDH1A1HTTKMT2ATP53 | |
| SCHEMBL12301882 | 0.73 | ALDH1A1 (0.86) | POLBALDH1A1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL24031087 | 0.72 | HDAC6 (1.00) | HDAC1HDAC8HDAC6 | |
| SCHEMBL16667740 | 0.71 | POLB (0.71) | POLBALDH1A1HTTTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499496-B2 | Inhibitors of respiratory syncytial virus | UNIVERSITY OF KANSAS (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150119411-A1 | INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS | UNIVERSITY OF KANSAS | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119411-A1 | INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS | SARS1, MAVS, RNASEH1 | POLB 230/4885ALDH1A1 4186/4885HTT 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.